We are now accepting abstract submissions!  The 2011 workshop will feature sessions on new basic science discoveries in autoimmunity and inflammation, new developments in the diagnosis of vasculitis, and the latest results of treatment trials.  Although there will be an emphasis on ANCA disease, sessions will be devoted to many major categories of vasculitis including small, medium and large vessel vasculitis.

Please note that the deadline for submitting scientific abstracts is December 10, 2010; 11:59 p.m. EST. We will only accept electronic submissions.

Abstract Categories

Important Deadlines

• Submission Deadline: December 10, 2010
• Response Date: January 7, 2011

Abstract Process

All abstracts submitted are peer reviewed. Authors’ names and institutions are not disclosed to reviewers.

Poster presentations at the 15th International Vasculitis & ANCA Workshop require an author’s presence at the poster during the viewing sessions. You will be contacted in advance of the meeting with your viewing date and times.

All authors who have abstracts accepted are expected to make their own travel arrangements, pay the meeting registration fees and cover their own travel and lodging expenses.

All abstracts will be included in Clinical & Experimental Immunology unless the first author requests removal of his/her abstract. To request removal of your abstract from the Abstract Supplement, please check the box (on your abstract submission form) which states “Please do not include my abstract in the Clinical & Experimental Immunology abstract supplement.”

On January 7, 2011, the first author of each submitted abstract will receive an e-mail notification regarding the status of his/her submitted abstract(s). If the first author does NOT receive an e-mail by January 8, 2011, please send an e-mail inquiry or fax your inquiry to (978) 304-0936. We cannot respond to abstract status inquires before January 7, 2011. It is the responsibility of the first author to contact non-presenting authors regarding abstract status.

Abstract Submission

All abstracts must be submitted electronically through the ANCA website by December 10, 2010; 11:59 p.m. EST.  An Abstract Submission Form must accompany each abstract submission. The submission site can be accessed through the ANCA website at www.agrimeetings.com/abstracts.

• Select one appropriate category for your abstract.
• Complete the Abstract Submission Form and upload with your abstract.
• You will receive an instant confirmation once your abstract has been submitted. If you do not receive this message, contact ANCA immediately by E-mail. Lack of confirmation indicates that your abstract was not received.
• Abstracts received after December 10, 2010; 11:59 p.m. EST will not be accepted or reviewed. No exceptions will be made.

Late-Breaking Clinical Trial Abstracts

Late-breaking abstracts must be submitted electronically through the ANCA website by March 2, 2011; 11:59 p.m. EST. The submission site can be accessed through the ANCA website at www.agrimeetings.com/abstracts. All accepted abstracts will be presented as oral presentation or displayed during the poster sessions. ANCA will accept a limited number of late-breaking abstracts for inclusion in the program.

General Information

Number of Submissions
There is no limit to the number of abstracts you may submit. Please note that the ANCA Program Committee will consider the total number of abstracts submitted by the same author when developing the program.

Abstracts may be withdrawn from publication before December 10, 2010; 11:59 p.m. EST. Please contact ANCA immediately by E-mail and provide your poster title and category.

You may resubmit an abstract. If you must make a minor change to your submitted abstract it will only be accepted as a re-submission by December 10, 2010; 11:59 p.m. EST. Only minor changes that do not affect the overall substance and content of your abstract (e.g., spelling) will be accepted. The resubmitted abstract will replace the original abstract. All other submission rules apply.

The abstracts are peer reviewed and authors’ names and institutions are not disclosed to reviewers. The results of a review will not be disclosed to an author.

All abstracts are included in the Abstract Supplement of Clinical & Experimental Immunology ; therefore, the copyright is transferred to ANCA for publication in all formats. If an abstract represents work done by individuals who work for the US Government, ANCA recognizes that the copyright ownership of this material is within the public domain and cannot therefore, be transferred to ANCA. The first author will be required to acknowledge a copyright transfer for each abstract submitted.

While not all abstracts are accepted for presentation in a free communication (oral) or poster presentation, all abstracts are included in the Abstract Supplement of Clinical & Experimental Immunology unless the first author requests to have the abstract removed from the publication prior to abstract submission; however, if the abstract is chosen for presentation, it must be included in the Abstract Supplement.

Rules & Regulations

Abstracts that were previously published as full manuscripts, either in print or as online papers in press, are ineligible for acceptance and will be rejected by ANCA. ANCA does accept abstracts submitted (but not yet accepted for presentation) to another scientific meeting. Due to copyright infringement policies, ANCA cannot accept or publish any abstract previously published in any publications where copyright has been transferred.

A first author must be designated for each abstract. The first author is responsible for giving the free communication (oral) or poster presentation if the abstract is accepted. Presenting authors should feel comfortable speaking and answering questions in English. This person will also serve as the primary contact person for ANCA and for all co-authors. The online abstract submission form asks for contact information for the first author. Please note that the abstract notification is sent via e-mail. If a change is made to the first authors contact information, please contact ANCA immediately by E-mail.

Please list all co-authors and their institutional names exactly as you would like them to appear in the final print and online publication. Make sure all co-authors approve the abstract submission, publication and potential presentation.

Formatting Abstract Text

• State purpose of study (preferably in one sentence).
• State methods used.
• Summarize presented results in sufficient detail to support the conclusions.
• State the conclusions reached.
• Include tables or images only if they are simple and fit within the allowable size limits. You may include both a table and an image but no more than one of each.
• Use standard abbreviations, e.g., RBC. Use kg., gm., mg., ml., L (liter), mEq., m (meter), mOsm (milliosmols), and % (percent). Place a special or unusual abbreviation in parentheses after the full word, the first time it appears.
• Use numerals to indicate numbers, except to begin sentences. Non-proprietary (generic) names of drugs should be used.
• Abstracts should be limited to 1800 characters.

Your abstract will automatically be rejected if the:

• Abstract is received after the deadline December 10, 2010; 11:59 p.m. EST.
• Abstract is submitted by fax or mail.
• Abstract category was not designated.
• Abstract was previously published as a full manuscript, either in print or as online paper in press.

Abstract Questions

Please direct abstract submission questions to ANCA at (978) 304-0935 or by E-mail.